Prediction of unfavorable outcomes in West Nile virus neuroinvasive infection - Result of a multinational ID-IRI study.


Journal

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671

Informations de publication

Date de publication:
01 2020
Historique:
received: 30 08 2019
revised: 31 10 2019
accepted: 07 11 2019
pubmed: 30 11 2019
medline: 7 2 2021
entrez: 29 11 2019
Statut: ppublish

Résumé

WNV causes 1.4% of all central nervous system infections and is the most common cause of epidemic neuro-invasive disease in humans. Our main objective was to investigate retrospectively West Nile virus neuroinvasive disease (WNND) cases hospitalized during 2010-2017 and identified factors that can influence prognosis. We documented the demographic, epidemiologic, clinical and laboratory data of WNND and identified factors that can influence prognosis. The data were recruited through Infectious Diseases International Research Initiative (ID-IRI), which serves as a network for clinical researches. We investigated 165 patients with WNND in 10 countries from three continents. 27 patients died and the mortality rate was 16.4%. In an univariate analysis age, congestive heart failure, neoplasm and ischemic heart disease (p < 0.001), neuropsychiatric disorders (p = 0.011), chronic hepatitis (p = 0.024) and hypertension (p = 0.043) were risk factors for death. Fatal evolution was also correlated with ICU addmission, disorientation, speech disorders, change in consciousnes, coma, a low Glasgow coma score, obtundation, confusion (p < 0.001), history of syncope (p = 0.002) and history of unconsciousness (p = 0.037). In a binomial logistic regresssion analysis only age and coma remained independent prediction factors for death. We created an equation that was calculated according to age, co-morbidities and clinical manifestations that may be used to establish the prognosis of WNND patients. WNND remain an important factor for morbidity and mortality worldwide, evolution to death or survival with sequelae are not rare. Our study creates an equation that may be used in the future to establish the prognosis of WNND patients.

Sections du résumé

BACKGROUND
WNV causes 1.4% of all central nervous system infections and is the most common cause of epidemic neuro-invasive disease in humans.
OBJECTIVES
Our main objective was to investigate retrospectively West Nile virus neuroinvasive disease (WNND) cases hospitalized during 2010-2017 and identified factors that can influence prognosis.
STUDY DESIGN
We documented the demographic, epidemiologic, clinical and laboratory data of WNND and identified factors that can influence prognosis. The data were recruited through Infectious Diseases International Research Initiative (ID-IRI), which serves as a network for clinical researches.
RESULTS
We investigated 165 patients with WNND in 10 countries from three continents. 27 patients died and the mortality rate was 16.4%. In an univariate analysis age, congestive heart failure, neoplasm and ischemic heart disease (p < 0.001), neuropsychiatric disorders (p = 0.011), chronic hepatitis (p = 0.024) and hypertension (p = 0.043) were risk factors for death. Fatal evolution was also correlated with ICU addmission, disorientation, speech disorders, change in consciousnes, coma, a low Glasgow coma score, obtundation, confusion (p < 0.001), history of syncope (p = 0.002) and history of unconsciousness (p = 0.037). In a binomial logistic regresssion analysis only age and coma remained independent prediction factors for death. We created an equation that was calculated according to age, co-morbidities and clinical manifestations that may be used to establish the prognosis of WNND patients.
CONCLUSIONS
WNND remain an important factor for morbidity and mortality worldwide, evolution to death or survival with sequelae are not rare. Our study creates an equation that may be used in the future to establish the prognosis of WNND patients.

Identifiants

pubmed: 31778945
pii: S1386-6532(19)30243-4
doi: 10.1016/j.jcv.2019.104213
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

104213

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Corneliu Petru Popescu (CP)

University of Medicine and Pharmacy Carol Davila Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest, Romania; ESCMID Study Group for Infectious Diseases of the Brain - ESGIB, Switzerland. Electronic address: corneliu.popescu@umfcd.ro.

Simin Aysel Florescu (SA)

University of Medicine and Pharmacy Carol Davila Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest, Romania.

Rodrigo Hasbun (R)

Department of Infectious Diseases, UT Health McGovern Medical School, Houston, TX, USA.

Arjan Harxhi (A)

Service of Infectious Disease, University Hospital Center of Tirana, Tirana, Albania.

Razi Evendar (R)

Infectious Diseases Institute, Rambam Health Care Campus, Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

Hasip Kahraman (H)

Ege University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.

Ami Neuberger (A)

Infectious Diseases Institute, Rambam Health Care Campus, Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.

Daniel Codreanu (D)

Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest, Romania.

Mihaela Florentina Zaharia (MF)

University of Medicine and Pharmacy Carol Davila Bucharest, Romania; Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest, Romania; ESCMID Study Group for Infectious Diseases of the Brain - ESGIB, Switzerland.

Selma Tosun (S)

Department of Infectious Diseases and Clinical Microbiology, Izmir Bozyaka Training and Research Hospital, Izmir, Turkey.

Emanoil Ceausu (E)

Dr Victor Babes Clinical Hospital of Infectious and Tropical Diseases Bucharest, Romania.

Simona Maria Ruta (SM)

University of Medicine and Pharmacy Carol Davila Bucharest, Romania; Stefan S. Nicolau Institute of Virology, Bucharest, Romania.

Gorana Dragovac (G)

Institute of Public Health of Vojvodina, Department of Prevention and Control of Diseases, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Epidemiology, Novi Sad, Serbia.

Natalia Pshenichnaya (N)

National Medical Research Center of Phthisiopulmonology and Infectious Diseases, Moscow, Russia; Central Scientific Research Laboratory, Rostov State Medical University, Rostov-on-Don, Russia.

Galina Gopatsa (G)

Department of Infectious Diseases, Rostov State Medical University, Rostov-on-Don, Russia.

Olga Shmaylenko (O)

Department of Infectious Diseases #5, City Hospital #1 named after N.A. Semashko, Rostov-on-Don, Russia.

Éva Nagy (É)

National Institute of Hematology and Infectious Diseases, Saint Laszlo Hospital, Budapest, Hungary.

Jelena Djekic Malbasa (JD)

Institute of Public Health of Vojvodina, Department of Prevention and Control of Diseases, Novi Sad, Serbia; University of Novi Sad, Faculty of Medicine, Department of Epidemiology, Novi Sad, Serbia.

Mirjana Strbac (M)

Institute of Public Health of Vojvodina, Department of Prevention and Control of Diseases, Novi Sad, Serbia.

Nenad Pandak (N)

General Hospital Slavonski Brod, Department for Infectious Diseases, School of Medicine, University of Split, Split, Croatia.

Husnu Pullukcu (H)

Ege University, School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey.

Botond Lakatos (B)

National Institute of Hematology and Infectious Diseases, Saint Laszlo Hospital, Budapest, Hungary.

Yasemin Cag (Y)

Department of Infectious Diseases and Clinical Microbiology, Medeniyet University, Goztepe Training and Research Hospital, Istanbul, Turkey.

Antonio Cascio (A)

Section of Infectious and Tropical Diseases, Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, Italy.

Ilaria Coledan (I)

Department of Diagnostics and Public Health, Section of Infectious Diseases, University of Verona, Verona, Italy.

Serkan Oncu (S)

Department of Infectious Diseases and Clinical Microbiology, Adnan Menderes University School of Medicine, Aydin, Turkey.

Hakan Erdem (H)

ESCMID Study Group for Infectious Diseases of the Brain - ESGIB, Switzerland; ID-IRI, Ankara, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH